Another recent phase II trial studying the efficacy of erlotinib, which also inhibits the tyrosine kinase domain of EGFR (Figure 1), and TMZ with RT for newly diagnosed GBM had to be stopped short of full accrual due to the lack of benefit and the unreasonable toxicity, including at least three treatment-related deaths [38]. The gene discussed is EGFR; the disease is glioblastoma.